Matthews O. Bradley, Ph.D.
Founder, Chairman, President, and Chief Technical Officer
Dr. Bradley has held key positions within the biopharmaceutical industry for 28 years and has extensive expertise in drug discovery and strategic drug development with a focus on target selection, drug proof of concept, preclinical pharmacology/toxicology, and IND/Phase I/II/III/NDA preparation in numerous therapeutic areas.
Prior to forming SAJE Pharma, Dr. Bradley ran his own consulting firm, working with small and mid-sized bio and pharmaceutical companies. He concentrated on developing strategic research and development plans for clients and on carrying out those plans using an extensive network of high quality, cost-efficient CROs.
Dr. Bradley has been the founder or co-founder of five previous biopharmaceutical companies where he has served in various executive R&D and board functions. Those companies include: Genetic MediSyn, Protarga, Replicon, Apothec, and Index Therapeutics. His work in those companies resulted in in-licenses, out-licenses, 18 patents, and numerous drugs discovered and developed through regulatory submissions.
Previously to these companies, Dr. Bradley worked for 12 years at Merck and Co., where he was Director of Safety Assessment and Biological Research. Before joining Merck, Dr. Bradley was a Senior Staff Fellow at the National Cancer Institute of the National Institutes of Health where he worked on cancer drug development. He has been involved in several worldwide regulatory submissions in the areas of allergy, neurology, infectious disease, cardiovascular disease, and oncology.
Dr. Bradley received a B.A. in Biology from The University of Pennsylvania and a Ph.D. in Biological Sciences from Stanford University. He was a Leukemia Society Postdoctoral Fellow at Stanford in the laboratory of Dr. Robert Schimke, where he studied molecular and cellular biology applied to mechanisms of aging and carcinogenesis. Dr. Bradley has authored 11 issued patents, 4 recent patent applications for GSNOR inhibitors, 70 peer-reviewed scientific publications, and numerous abstracts, book chapters, reviews, and published symposium conferences.
Helen S. Pentikis, Ph.D.
Founder, Chief Executive Officer, and Chief Scientific Officer
Dr. Pentikis has also been working at high levels within the pharmaceutical and biopharmaceutical industries for over 2o years and has extensive expertise in regulatory and strategic drug development with a focus on pharmacokinetics (PK), pharmacodynamics (PD), and biopharmaceutics involving numerous therapeutic areas.
Prior to forming SAJE Pharma, Dr. Pentikis served as Head, Clinical Pharmacology at AkaRx Inc., an emerging pharmaceutical company. Dr. Pentikis was responsible for all clinical pharmacology activities and management for the company’s lead oncology product. Dr. Pentikis’ work and position on the senior management team was instrumental in the $300M acquisition of AkaRx.
Previously, Dr. Pentikis was Global Vice President, Pharmacokinetics and Pharmacodynamics at ICON plc (formerly GloboMax LLC) and was responsible for the scientific management of all PK and biostatistics teams. Dr. Pentikis was a Research Fellow in the Pharmacometrics section at Sanofi-Aventis where she successfully applied PK and PD principles to the design of Phase I-III studies and their interpretation. Dr. Pentikis was involved in several worldwide regulatory submissions in the areas of women’s health, allergy, and oncology supportive care.
Dr. Pentikis received a B.S. in Biology from Wake Forest University, and a Ph.D. in Pharmacology and Toxicology from the University of Maryland. Dr. Pentikis completed a Pharmacokinetics Fellowship at the FDA where she studied population PK and PD mixed effects modeling and in vitro drug metabolism using human liver microsomes. Dr. Pentikis has 18 peer-reviewed scientific publications and numerous abstracts, book chapters, and published symposium talks.
Richard J. Pariza, Ph.D.
Senior Vice President, Chemistry
Dr. Pariza joined SAJE in 2013 and has been instrumental in developing the Company’s chemistry program. He has designed and synthesized novel GSNOR inhibitors using the Company’s proprietary structural-activity knowledge. Many of those molecules are advancing in preclinical evaluations.
Dr. Pariza started his pharmaceutical career at Abbott Laboratories Pharmaceutical Division in the chemistry group designing and synthesizing novel molecules for various targets. As well, he founded and ran a process research group. After Abbott, Dr. Pariza was a consultant to G.D. Searle and other pharmaceutical companies on chemistry related issues. He has also been a lead chemist at the senior executive level for a number of biopharmaceutical companies including Protarga, Natural Pharmaceuticals, Cedarburg Pharmaceuticals, OncQuest, Inc., and C-NOF Pharmaceuticals.
Dr. Pariza received a B.S. degree in chemistry from the University of Wisconsin and a Ph.D. from Purdue University in organic chemistry. Dr. Pariza has authored 16 issued patents and 24 peer-reviewed scientific publications and numerous abstracts, book chapters, and published symposium talks.
